Dietary Supplementation with the Probiotic Bacillus velezensis BV379 Decreases Abdominal Bloating Without Perturbing the Commensal Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Adults.

IF 2.6 4区 医学 Q1 NUTRITION & DIETETICS
Sean M Garvey, Traci M Blonquist, Laura M Brutscher, Dana M Walsh, Valerie N Kaden, Dawn B Beckman, Min Zeng, Richard S Bruno, Chad M Cook, Jessica L Spears
{"title":"Dietary Supplementation with the Probiotic <i>Bacillus velezensis</i> BV379 Decreases Abdominal Bloating Without Perturbing the Commensal Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Adults.","authors":"Sean M Garvey, Traci M Blonquist, Laura M Brutscher, Dana M Walsh, Valerie N Kaden, Dawn B Beckman, Min Zeng, Richard S Bruno, Chad M Cook, Jessica L Spears","doi":"10.1080/27697061.2025.2563894","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Various bacterial <i>Bacillaceae</i> and <i>Bacillus</i> strains have demonstrated health benefits, but less is known about probiotic characteristics of strains of <i>Bacillus velezensis</i>. In this randomized, double-blind, placebo-controlled clinical trial, we investigated the safety and efficacy of <i>B. velezensis</i> BV379 supplementation for 8 weeks (2 × 10<sup>9</sup> colony-forming units (CFU)/day).</p><p><strong>Methods: </strong>During the baseline and final weeks, GI symptoms were recorded daily using the 8-item Gastrointestinal Tolerance Questionnaire (GITQ). The primary outcome was the proportion of participants showing an improvement from baseline to week 8 in the 7-day, 3-item composite score for abdominal distention/bloating, burping, and gas/flatulence. Plasma chemistry, hematology, intestinal permeability, and fecal metagenomes were also investigated.</p><p><strong>Results: </strong>Eighty participants (54% female; age: 50.3 ± 10.1 years) were randomized to BV379 (<i>n</i> = 39) or placebo (<i>n</i> = 41). At end of study, no significant difference was observed in the percentage of participants with improvement in the 3-item composite GITQ score (BV379: 36.1%; placebo: 28.2%; <i>p</i> = 0.46). Analysis of individual GI symptoms showed that more participants experienced improvement in abdominal distention/bloating with BV379 compared to placebo (38.9% vs 17.9%; <i>p</i> = 0.044). There were no clinically meaningful changes in plasma chemistry, hematology, or intestinal permeability between groups. Fecal metagenomic analyses showed no overall shifts in microbial composition between groups. In addition to <i>B. velezensis</i>, a few commensal species such as <i>Lacticasei bacillus casei</i> were significantly enriched in the BV379 group.</p><p><strong>Conclusion: </strong>Despite not significantly improving the composite GITQ score of distention/bloating, burping, and gas/flatulence, BV379 supplementation was a well-tolerated approach to specifically lower abdominal bloating.</p>","PeriodicalId":29768,"journal":{"name":"Journal of the American Nutrition Association","volume":" ","pages":"1-16"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Nutrition Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/27697061.2025.2563894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Various bacterial Bacillaceae and Bacillus strains have demonstrated health benefits, but less is known about probiotic characteristics of strains of Bacillus velezensis. In this randomized, double-blind, placebo-controlled clinical trial, we investigated the safety and efficacy of B. velezensis BV379 supplementation for 8 weeks (2 × 109 colony-forming units (CFU)/day).

Methods: During the baseline and final weeks, GI symptoms were recorded daily using the 8-item Gastrointestinal Tolerance Questionnaire (GITQ). The primary outcome was the proportion of participants showing an improvement from baseline to week 8 in the 7-day, 3-item composite score for abdominal distention/bloating, burping, and gas/flatulence. Plasma chemistry, hematology, intestinal permeability, and fecal metagenomes were also investigated.

Results: Eighty participants (54% female; age: 50.3 ± 10.1 years) were randomized to BV379 (n = 39) or placebo (n = 41). At end of study, no significant difference was observed in the percentage of participants with improvement in the 3-item composite GITQ score (BV379: 36.1%; placebo: 28.2%; p = 0.46). Analysis of individual GI symptoms showed that more participants experienced improvement in abdominal distention/bloating with BV379 compared to placebo (38.9% vs 17.9%; p = 0.044). There were no clinically meaningful changes in plasma chemistry, hematology, or intestinal permeability between groups. Fecal metagenomic analyses showed no overall shifts in microbial composition between groups. In addition to B. velezensis, a few commensal species such as Lacticasei bacillus casei were significantly enriched in the BV379 group.

Conclusion: Despite not significantly improving the composite GITQ score of distention/bloating, burping, and gas/flatulence, BV379 supplementation was a well-tolerated approach to specifically lower abdominal bloating.

在健康成人中,膳食补充益生菌velezensis BV379可减少腹胀而不干扰共生肠道微生物群:一项随机、双盲、安慰剂对照试验
目的:多种芽孢杆菌科和芽孢杆菌菌株已被证明具有健康益处,但对velezensis芽孢杆菌菌株的益生菌特性知之甚少。在这项随机、双盲、安慰剂对照的临床试验中,我们研究了贝氏B. velezensis BV379补充8周(2 × 109菌落形成单位(CFU)/天)的安全性和有效性。方法:在基线和最后几周,每天使用8项胃肠耐受性问卷(GITQ)记录胃肠道症状。主要结果是在7天的腹胀/腹胀、打嗝和气/胀气的3项综合评分中,从基线到第8周显示改善的参与者比例。血浆化学、血液学、肠通透性和粪便宏基因组也进行了研究。结果:80名参与者(54%为女性,年龄50.3±10.1岁)被随机分为BV379组(n = 39)和安慰剂组(n = 41)。在研究结束时,3项综合GITQ评分改善的参与者百分比无显著差异(BV379: 36.1%;安慰剂:28.2%;p = 0.46)。对个体胃肠道症状的分析显示,与安慰剂相比,BV379组更多的参与者经历了腹胀/腹胀的改善(38.9% vs 17.9%; p = 0.044)。两组之间血浆化学、血液学或肠通透性均无临床意义的变化。粪便宏基因组分析显示,各组之间的微生物组成没有总体变化。在BV379组中,除B. velezensis外,一些共生菌如干酪乳杆菌(Lacticasei bacillus casei)也显著富集。结论:尽管没有显著改善胀/腹胀、打嗝和气/胀气的综合GITQ评分,但补充BV379是一种耐受性良好的治疗下腹部腹胀的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信